Differences in expression of junctional adhesion molecule-A and [beta]-catenin in multiple sclerosis brain tissue: increasing evidence for the role of tight junction pathology

Previously we have employed antibodies to the tight junction (TJ)-associated proteins ZO-1 and occludin to describe endothelial tight junction abnormalities, in lesional and normal appearing white matter, in primary and secondary progressive multiple sclerosis (MS). This work is extended here by use...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta neuropathologica 2007-02, Vol.113 (2), p.177
Hauptverfasser: Padden, Maureen, Leech, Susie, Craig, Beverly, Kirk, John, Brankin, Brenda, McQuaid, Stephen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 2
container_start_page 177
container_title Acta neuropathologica
container_volume 113
creator Padden, Maureen
Leech, Susie
Craig, Beverly
Kirk, John
Brankin, Brenda
McQuaid, Stephen
description Previously we have employed antibodies to the tight junction (TJ)-associated proteins ZO-1 and occludin to describe endothelial tight junction abnormalities, in lesional and normal appearing white matter, in primary and secondary progressive multiple sclerosis (MS). This work is extended here by use of antibodies to the independent TJ-specific proteins and junctional adhesion molecule A & B (JAM-A, JAM-B). We have also assessed the expression in MS of β-catenin, a protein specific to the TJ-associated adherens junction. Immunocytochemistry and semiquantitative confocal microscopy for JAM-A and β-catenin was performed on snap-frozen sections from MS cases (n = 11) and controls (n = 6). Data on 1,443 blood vessels was acquired from active lesions (n = 13), inactive lesions (n = 13), NAWM (n = 20) and control white matter (n = 13). In MS abnormal JAM-A expression was found in active (46%) and inactive lesions (21%), comparable to previous data using ZO-1. However, a lower level of TJ abnormality was found in MS NAWM using JAM-A (3%) compared to ZO-1 (13%). JAM-B was strongly expressed on a small number of large blood vessels in control and MS tissues but at too low a level for quantitative analysis. By comparison with the high levels of abnormality observed with the TJ proteins, the adherens junction protein β-catenin was normally expressed in all MS and control tissue categories. These results confirm, by use of the independent marker JAM-A, that TJ abnormalities are most frequent in active white matter lesions. Altered expression of JAM-A, in addition to affecting junctional tightness may also both reflect and affect leukocyte trafficking, with implications for immune status within the diseased CNS. Conversely, the adherens junction component of the TJ, as indicated by β-catenin expression is normally expressed in all MS and control tissue categories.
doi_str_mv 10.1007/s00401-006-0145-x
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_211894302</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1204602511</sourcerecordid><originalsourceid>FETCH-proquest_journals_2118943023</originalsourceid><addsrcrecordid>eNqNjktOxDAMhiMEEuVxAHYW-4CTtjPADgEjDsAOoVGmddtUmaTEKRpOxRXJIMQayZIf_29_FuJC4ZVCXF4zYoVKIi4kqqqWuwNRqKrUEuuyPBQFYlYXpdbH4oR5zJ1eVnUhvh5t11Ek3xCD9UC7KRKzDR5CB-Psm5Rr48C0A_2Mt8FRMzuS92B8C68bSuZNNiaRz_s5trNLdnIE3DiKgS3DJposJMs80132NJEMW98Dfdh2z4YuREgDQczX9-Rk-yH98WEyaQgu9J9n4qgzjun8N5-Ky9XTy8OznGJ4n4nTegxzzA_zWit1c1uVqMt_mb4B6oNpYw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>211894302</pqid></control><display><type>article</type><title>Differences in expression of junctional adhesion molecule-A and [beta]-catenin in multiple sclerosis brain tissue: increasing evidence for the role of tight junction pathology</title><source>SpringerLink Journals - AutoHoldings</source><creator>Padden, Maureen ; Leech, Susie ; Craig, Beverly ; Kirk, John ; Brankin, Brenda ; McQuaid, Stephen</creator><creatorcontrib>Padden, Maureen ; Leech, Susie ; Craig, Beverly ; Kirk, John ; Brankin, Brenda ; McQuaid, Stephen</creatorcontrib><description>Previously we have employed antibodies to the tight junction (TJ)-associated proteins ZO-1 and occludin to describe endothelial tight junction abnormalities, in lesional and normal appearing white matter, in primary and secondary progressive multiple sclerosis (MS). This work is extended here by use of antibodies to the independent TJ-specific proteins and junctional adhesion molecule A &amp; B (JAM-A, JAM-B). We have also assessed the expression in MS of β-catenin, a protein specific to the TJ-associated adherens junction. Immunocytochemistry and semiquantitative confocal microscopy for JAM-A and β-catenin was performed on snap-frozen sections from MS cases (n = 11) and controls (n = 6). Data on 1,443 blood vessels was acquired from active lesions (n = 13), inactive lesions (n = 13), NAWM (n = 20) and control white matter (n = 13). In MS abnormal JAM-A expression was found in active (46%) and inactive lesions (21%), comparable to previous data using ZO-1. However, a lower level of TJ abnormality was found in MS NAWM using JAM-A (3%) compared to ZO-1 (13%). JAM-B was strongly expressed on a small number of large blood vessels in control and MS tissues but at too low a level for quantitative analysis. By comparison with the high levels of abnormality observed with the TJ proteins, the adherens junction protein β-catenin was normally expressed in all MS and control tissue categories. These results confirm, by use of the independent marker JAM-A, that TJ abnormalities are most frequent in active white matter lesions. Altered expression of JAM-A, in addition to affecting junctional tightness may also both reflect and affect leukocyte trafficking, with implications for immune status within the diseased CNS. Conversely, the adherens junction component of the TJ, as indicated by β-catenin expression is normally expressed in all MS and control tissue categories.</description><identifier>ISSN: 0001-6322</identifier><identifier>EISSN: 1432-0533</identifier><identifier>DOI: 10.1007/s00401-006-0145-x</identifier><language>eng</language><publisher>Heidelberg: Springer Nature B.V</publisher><subject>Blood vessels ; Brain research ; Cytokines ; Endothelium ; Leukocytes ; Multiple sclerosis ; Pathology ; Proteins</subject><ispartof>Acta neuropathologica, 2007-02, Vol.113 (2), p.177</ispartof><rights>Springer-Verlag 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Padden, Maureen</creatorcontrib><creatorcontrib>Leech, Susie</creatorcontrib><creatorcontrib>Craig, Beverly</creatorcontrib><creatorcontrib>Kirk, John</creatorcontrib><creatorcontrib>Brankin, Brenda</creatorcontrib><creatorcontrib>McQuaid, Stephen</creatorcontrib><title>Differences in expression of junctional adhesion molecule-A and [beta]-catenin in multiple sclerosis brain tissue: increasing evidence for the role of tight junction pathology</title><title>Acta neuropathologica</title><description>Previously we have employed antibodies to the tight junction (TJ)-associated proteins ZO-1 and occludin to describe endothelial tight junction abnormalities, in lesional and normal appearing white matter, in primary and secondary progressive multiple sclerosis (MS). This work is extended here by use of antibodies to the independent TJ-specific proteins and junctional adhesion molecule A &amp; B (JAM-A, JAM-B). We have also assessed the expression in MS of β-catenin, a protein specific to the TJ-associated adherens junction. Immunocytochemistry and semiquantitative confocal microscopy for JAM-A and β-catenin was performed on snap-frozen sections from MS cases (n = 11) and controls (n = 6). Data on 1,443 blood vessels was acquired from active lesions (n = 13), inactive lesions (n = 13), NAWM (n = 20) and control white matter (n = 13). In MS abnormal JAM-A expression was found in active (46%) and inactive lesions (21%), comparable to previous data using ZO-1. However, a lower level of TJ abnormality was found in MS NAWM using JAM-A (3%) compared to ZO-1 (13%). JAM-B was strongly expressed on a small number of large blood vessels in control and MS tissues but at too low a level for quantitative analysis. By comparison with the high levels of abnormality observed with the TJ proteins, the adherens junction protein β-catenin was normally expressed in all MS and control tissue categories. These results confirm, by use of the independent marker JAM-A, that TJ abnormalities are most frequent in active white matter lesions. Altered expression of JAM-A, in addition to affecting junctional tightness may also both reflect and affect leukocyte trafficking, with implications for immune status within the diseased CNS. Conversely, the adherens junction component of the TJ, as indicated by β-catenin expression is normally expressed in all MS and control tissue categories.</description><subject>Blood vessels</subject><subject>Brain research</subject><subject>Cytokines</subject><subject>Endothelium</subject><subject>Leukocytes</subject><subject>Multiple sclerosis</subject><subject>Pathology</subject><subject>Proteins</subject><issn>0001-6322</issn><issn>1432-0533</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqNjktOxDAMhiMEEuVxAHYW-4CTtjPADgEjDsAOoVGmddtUmaTEKRpOxRXJIMQayZIf_29_FuJC4ZVCXF4zYoVKIi4kqqqWuwNRqKrUEuuyPBQFYlYXpdbH4oR5zJ1eVnUhvh5t11Ek3xCD9UC7KRKzDR5CB-Psm5Rr48C0A_2Mt8FRMzuS92B8C68bSuZNNiaRz_s5trNLdnIE3DiKgS3DJposJMs80132NJEMW98Dfdh2z4YuREgDQczX9-Rk-yH98WEyaQgu9J9n4qgzjun8N5-Ky9XTy8OznGJ4n4nTegxzzA_zWit1c1uVqMt_mb4B6oNpYw</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>Padden, Maureen</creator><creator>Leech, Susie</creator><creator>Craig, Beverly</creator><creator>Kirk, John</creator><creator>Brankin, Brenda</creator><creator>McQuaid, Stephen</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>20070201</creationdate><title>Differences in expression of junctional adhesion molecule-A and [beta]-catenin in multiple sclerosis brain tissue: increasing evidence for the role of tight junction pathology</title><author>Padden, Maureen ; Leech, Susie ; Craig, Beverly ; Kirk, John ; Brankin, Brenda ; McQuaid, Stephen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_2118943023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Blood vessels</topic><topic>Brain research</topic><topic>Cytokines</topic><topic>Endothelium</topic><topic>Leukocytes</topic><topic>Multiple sclerosis</topic><topic>Pathology</topic><topic>Proteins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Padden, Maureen</creatorcontrib><creatorcontrib>Leech, Susie</creatorcontrib><creatorcontrib>Craig, Beverly</creatorcontrib><creatorcontrib>Kirk, John</creatorcontrib><creatorcontrib>Brankin, Brenda</creatorcontrib><creatorcontrib>McQuaid, Stephen</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Acta neuropathologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Padden, Maureen</au><au>Leech, Susie</au><au>Craig, Beverly</au><au>Kirk, John</au><au>Brankin, Brenda</au><au>McQuaid, Stephen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differences in expression of junctional adhesion molecule-A and [beta]-catenin in multiple sclerosis brain tissue: increasing evidence for the role of tight junction pathology</atitle><jtitle>Acta neuropathologica</jtitle><date>2007-02-01</date><risdate>2007</risdate><volume>113</volume><issue>2</issue><spage>177</spage><pages>177-</pages><issn>0001-6322</issn><eissn>1432-0533</eissn><abstract>Previously we have employed antibodies to the tight junction (TJ)-associated proteins ZO-1 and occludin to describe endothelial tight junction abnormalities, in lesional and normal appearing white matter, in primary and secondary progressive multiple sclerosis (MS). This work is extended here by use of antibodies to the independent TJ-specific proteins and junctional adhesion molecule A &amp; B (JAM-A, JAM-B). We have also assessed the expression in MS of β-catenin, a protein specific to the TJ-associated adherens junction. Immunocytochemistry and semiquantitative confocal microscopy for JAM-A and β-catenin was performed on snap-frozen sections from MS cases (n = 11) and controls (n = 6). Data on 1,443 blood vessels was acquired from active lesions (n = 13), inactive lesions (n = 13), NAWM (n = 20) and control white matter (n = 13). In MS abnormal JAM-A expression was found in active (46%) and inactive lesions (21%), comparable to previous data using ZO-1. However, a lower level of TJ abnormality was found in MS NAWM using JAM-A (3%) compared to ZO-1 (13%). JAM-B was strongly expressed on a small number of large blood vessels in control and MS tissues but at too low a level for quantitative analysis. By comparison with the high levels of abnormality observed with the TJ proteins, the adherens junction protein β-catenin was normally expressed in all MS and control tissue categories. These results confirm, by use of the independent marker JAM-A, that TJ abnormalities are most frequent in active white matter lesions. Altered expression of JAM-A, in addition to affecting junctional tightness may also both reflect and affect leukocyte trafficking, with implications for immune status within the diseased CNS. Conversely, the adherens junction component of the TJ, as indicated by β-catenin expression is normally expressed in all MS and control tissue categories.</abstract><cop>Heidelberg</cop><pub>Springer Nature B.V</pub><doi>10.1007/s00401-006-0145-x</doi></addata></record>
fulltext fulltext
identifier ISSN: 0001-6322
ispartof Acta neuropathologica, 2007-02, Vol.113 (2), p.177
issn 0001-6322
1432-0533
language eng
recordid cdi_proquest_journals_211894302
source SpringerLink Journals - AutoHoldings
subjects Blood vessels
Brain research
Cytokines
Endothelium
Leukocytes
Multiple sclerosis
Pathology
Proteins
title Differences in expression of junctional adhesion molecule-A and [beta]-catenin in multiple sclerosis brain tissue: increasing evidence for the role of tight junction pathology
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A21%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differences%20in%20expression%20of%20junctional%20adhesion%20molecule-A%20and%20%5Bbeta%5D-catenin%20in%20multiple%20sclerosis%20brain%20tissue:%20increasing%20evidence%20for%20the%20role%20of%20tight%20junction%20pathology&rft.jtitle=Acta%20neuropathologica&rft.au=Padden,%20Maureen&rft.date=2007-02-01&rft.volume=113&rft.issue=2&rft.spage=177&rft.pages=177-&rft.issn=0001-6322&rft.eissn=1432-0533&rft_id=info:doi/10.1007/s00401-006-0145-x&rft_dat=%3Cproquest%3E1204602511%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=211894302&rft_id=info:pmid/&rfr_iscdi=true